PYCXF.US PYC Therapeutics Limited

Healthcare Biotechnology USA Stocks
1.22 USD
Close of Nov 18, 2026
0.8462 1.80
Market cap
USD 1.20B
P/E
-
P/B
2.56x
ROE
-6.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is PYCXF.US undervalued?

Graham number

The Graham number of PYC Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PYC Therapeutics Limited fundamental analysis

No fundamental analysis for PYC Therapeutics Limited yet.

PYC Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PYC Therapeutics Limited

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic …

Full company profile